Menu
Sign In Search Podcasts Libraries Charts People & Topics Add Podcast API Blog Pricing

Bristol-Myers Squibb in Podcasts

company

Bristol-Myers Squibb is a global pharmaceutical company that acquired a biotech company involved in cell therapy.

Mentions Over Time

12 mentions

Mentions in Podcasts

Motley Fool Hidden Gems Investing
Another Semiconductor Stock Is Headed to the S&P 500

Both Bristol-Myers and Pfizer would be classified in the high yield category.

Motley Fool Hidden Gems Investing
Another Semiconductor Stock Is Headed to the S&P 500

Bristol-Myers is around 70%.

Motley Fool Hidden Gems Investing
Another Semiconductor Stock Is Headed to the S&P 500

Bristol-Myers is around 4.4%.

Motley Fool Hidden Gems Investing
Another Semiconductor Stock Is Headed to the S&P 500

So Bristol-Myers Squibb, how would you compare them to Pfizer and other competitors?

Motley Fool Hidden Gems Investing
Another Semiconductor Stock Is Headed to the S&P 500

Again, this is not uncommon in the world of pharma, but it is very much the dynamic we've been seeing with Bristol-Myers.

Motley Fool Hidden Gems Investing
Another Semiconductor Stock Is Headed to the S&P 500

And one of the biggest challenges that Bristol-Myers Squibb has been

Motley Fool Hidden Gems Investing
Another Semiconductor Stock Is Headed to the S&P 500

But it also, on the flip side of that, it saddled Bristol-Myers Squibb with massive debt, as well as some structural dependencies that they're still trying to outrun.